- Home
- TEL vs REGN Comparison
TEL vs REGN Comparison
Compare TEL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEL
- REGN
- Stock Information
- Founded
- TEL 1941
- REGN 1988
- Country
- TEL Ireland
- REGN United States
- Employees
- TEL N/A
- REGN N/A
- Industry
- TEL Industrial Machinery/Components
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- TEL Technology
- REGN Health Care
- Exchange
- TEL Nasdaq
- REGN Nasdaq
- Market Cap
- TEL 61.0B
- REGN 59.5B
- IPO Year
- TEL 2007
- REGN 1991
- Fundamental
- Price
- TEL $204.98
- REGN $589.48
- Analyst Decision
- TEL Buy
- REGN Buy
- Analyst Count
- TEL 10
- REGN 22
- Target Price
- TEL $196.50
- REGN $806.32
- AVG Volume (30 Days)
- TEL 1.7M
- REGN 1.0M
- Earning Date
- TEL 07-23-2025
- REGN 08-01-2025
- Dividend Yield
- TEL 1.39%
- REGN 0.60%
- EPS Growth
- TEL N/A
- REGN 5.03
- EPS
- TEL 4.83
- REGN 39.67
- Revenue
- TEL $16,581,000,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- TEL $8.43
- REGN N/A
- Revenue Next Year
- TEL $8.27
- REGN $6.65
- P/E Ratio
- TEL $42.42
- REGN $14.86
- Revenue Growth
- TEL 4.86
- REGN 5.38
- 52 Week Low
- TEL $116.30
- REGN $476.49
- 52 Week High
- TEL $212.76
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- TEL 62.39
- REGN 60.67
- Support Level
- TEL $198.00
- REGN $570.39
- Resistance Level
- TEL $208.70
- REGN $585.00
- Average True Range (ATR)
- TEL 3.65
- REGN 16.72
- MACD
- TEL -1.33
- REGN 2.93
- Stochastic Oscillator
- TEL 65.23
- REGN 68.39
About TEL TE Connectivity Ltd. New Switzerland Registered Shares
TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).